FDA Accepts NDA for SH-201 in Leukemia and Other Cancers

The FDA has accepted the new drug application (NDA) for SH-201, the first palatable oral liquid of the related chemotherapeutic agent, for the treatment of certain forms of leukemia and other cancers.

“With this NDA acceptance for SH-201, we are a step closer to providing an alternative treatment to thousands of United States patients diagnosed with leukemia and other cancers who do not currently have the option of an oral liquid,” Sharon Cunningham, CEO and Co-Founder of Shorla Oncology.

Read more here: Article